The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials
| Autor: | Alisa J. Stephens-Shields, Peter Preston, Xiaoling Hou, Jill P. Crandall, Nanette K. Wenger, Marco Pahor, Emile R. Mohler, Ronald S. Swerdloff, Elizabeth Barrett-Connor, Glenn R. Cunningham, Michael R. Lewis, Thomas M. Gill, Alvin M. Matsumoto, Kristine E. Ensrud, Jane A. Cauley, Denise Cifelli, Mark E. Molitch, Shalender Bhasin, Peter J. Snyder, Cora E. Lewis, Susan S. Ellenberg, Matthew J. Budoff |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Aging Hormone Replacement Therapy Endocrinology Diabetes and Metabolism medicine.medical_treatment Clinical Biochemistry Clinical Sciences 030209 endocrinology & metabolism Context (language use) and over 030204 cardiovascular system & hematology Placebo Biochemistry Cardiovascular System law.invention Paediatrics and Reproductive Medicine 03 medical and health sciences chemistry.chemical_compound Endocrinology & Metabolism 0302 clinical medicine Endocrinology Randomized controlled trial Double-Blind Method law Internal medicine Fibrinolysis 80 and over Medicine Humans Testosterone Aged Aged 80 and over business.industry Cholesterol Insulin Hypogonadism Biochemistry (medical) Testosterone (patch) United States Testosterone Gel chemistry Corrigendum business Biomarkers |
| Zdroj: | The Journal of clinical endocrinology and metabolism, vol 103, iss 2 III, MER; Ellenberg, SS; Lewis, CE; Wenger, NK; Budoff, MJ; Lewis, MR; et al.(2018). The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 103(2), 681-688. doi: 10.1210/jc.2017-02243. UCLA: Retrieved from: http://www.escholarship.org/uc/item/34f46044 |
| DOI: | 10.1210/jc.2017-02243. |
| Popis: | Context Studies of the possible cardiovascular risk of testosterone treatment are inconclusive. Objective To determine the effect of testosterone treatment on cardiovascular biomarkers in older men with low testosterone. Design Double-blind, placebo-controlled trial. Setting Twelve academic medical centers in the United States. Participants In all, 788 men ≥65 years old with an average of two serum testosterone levels Intervention Testosterone gel, the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months. Main Outcome Measures Serum markers of cardiovascular risk, including lipids and markers of glucose metabolism, fibrinolysis, inflammation, and myocardial damage. Results Compared with placebo, testosterone treatment significantly decreased total cholesterol (adjusted mean difference, −6.1 mg/dL; P < 0.001), high-density lipoprotein cholesterol (adjusted mean difference, −2.0 mg/dL; P < 0.001), and low-density lipoprotein cholesterol (adjusted mean difference, −2.3 mg/dL; P = 0.051) from baseline to month 12. Testosterone also slightly but significantly decreased fasting insulin (adjusted mean difference, −1.7 µIU/mL; P = 0.02) and homeostatic model assessment‒insulin resistance (adjusted mean difference, −0.6; P = 0.03). Testosterone did not change triglycerides, d-dimer, C-reactive protein, interleukin 6, troponin, glucose, or hemoglobin A1c levels more than placebo. Conclusions and Relevance Testosterone treatment of 1 year in older men with low testosterone was associated with small reductions in cholesterol and insulin but not with other glucose markers, markers of inflammation or fibrinolysis, or troponin. The clinical importance of these findings is unclear and requires a larger trial of clinical outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|